- The ImmunityBio and NantKwest merger has created a clinical powerhouse in immunotherapy. The share price continues to show weakness since the merger with little reaction to positive news.
- It is possible the market has lost sight of IBRX, despite several programs moving closer to the finish line.
- The company’s COVID-19 vaccine candidate continues to move forward and could be a best-in-class product as a primary and booster to help thwart the Delta Variant.
- I remain bullish at these prices and will provide an update on my IBRX strategy.
For further details see:
ImmunityBio: Market Has Lost Contact Following Merger